Series B Round

Zucara Therapeutics Inc. has successfully completed a $25 million Series B financing round aimed at advancing its innovative therapies for diabetes management, particularly focusing on hypoglycemia prevention. This funding will support the completion of their Phase 2a clinical trial and various nonclinical activities. The financing round saw participation from notable investors including Sanofi, Perceptive Xontogeny Venture Fund, and T1D Fund, reflecting strong confidence in Zucara's mission to improve the lives of people living with diabetes. The funds will also be utilized for further research and development of their lead product candidate, which aims to provide a first-in-class solution for hypoglycemia prevention in diabetes patients. This financing round marks a significant milestone for Zucara as it continues to innovate in the diabetes therapeutics space.